NXP001 Update
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your NFX notes
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that the Company has achieved the second milestone according to its updated NXP001 exclusive licensing agreement with Oxilio Ltd ("Oxilio") and received the associated payment.
Commenting, Dr Dan Gooding, Executive Director of Nuformix, said: "Oxilio is progressing NXP001 with Nuformix's full support. We are pleased to have triggered the second milestone payment as per the terms of our updated agreement. Funds received continue to assist in advancing our core NXP002 and NXP004 programmes as we progress partnering interactions for these programmes."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.